Navigating the immunosuppressive abyss: current hurdles and innovative breakthroughs in neoadjuvant immunotherapy for osteosarcoma
Osteosarcoma is the most common primary malignant bone tumor of children and adolescents. Multiagent neoadjuvant chemotherapy once improved survival substantially, but outcomes have since plateaued. Delivering immunotherapy before surgery is attractive…